Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


June 03, 2015 10:14 AM ET

Diversified Consumer Services

Company Overview of The Hong Kong Polytechnic University

Company Overview

The Hong Kong Polytechnic University is an educational institution.

11/F

Li Ka Shing Tower

Hung Hom

Hong Kong,  

Hong Kong

Key Executives for The Hong Kong Polytechnic University

The Hong Kong Polytechnic University does not have any Key Executives recorded.

The Hong Kong Polytechnic University Key Developments

The Hong Kong Polytechnic University Presents at 11th China Hotel Investment Conference (CHIC), May-12-2015

The Hong Kong Polytechnic University Presents at 11th China Hotel Investment Conference (CHIC), May-12-2015 . Venue: Mandarin Oriental Pudong, Shanghai, China. Speakers: Xiao Qu, Program Leader, Hotel and Tourism Management (China) Program.

Kinex Pharmaceuticals Licenses Patents from Hong Kong Polytechnic University and McGill University

Kinex Pharmaceuticals announced the exclusive licensing of global rights of three patents from The Hong Kong Polytechnic University and McGill University. These three patents covered the inventions by Professor Larry Chow and Professor William Chan including novel new chemical compounds that have nanomolar potency against a molecular target named Breast Cancer Resistance Protein (BCRP). BCRP is a protein pump known to pump drugs, including anticancer drugs, from cancer cells that can lead to drug resistance; and also to pump drugs back into gastrointestinal tract, which prevent some useful drugs to be delivered to their target. The development of this technology, if successful, will expand the current Kinex oral drug absorption development platform. That platform currently includes the inhibition of P-glycoprotein that Kinex licensed from Hanmi in 2011. The lead molecule, HM30181A, has been shown in clinical studies to enhance the absorption of anticancer drugs including paclitaxel and irinotecan into orally available drugs. The lead program, Oraxol (an oral form of paclitaxel), has demonstrated clinical efficacy and an excellent safety profile in patient studies. Kinex is also actively developing other proprietary oral drug delivery platforms. The addition of another oral absorption delivery technology platform will further strengthen Kinex's arsenal of converting greater classes of intravenous drugs into oral versions. The terms of this exclusive license include upfront payments, milestones and royalties. Kinex is also committing to support research programs in Professor Larry Chow's laboratory to further develop this platform collaboratively with Kinex.

Advanced Biological Laboratories, The University of Hong Kong and The Hong Kong Polytechnic University Decide to Join Forces to Develop a Deep-Sequencing Tuberculosis Solution

Advanced Biological Laboratories (ABL), S.A, The University of Hong Kong and The Hong Kong Polytechnic University announced the launching their collaborative tuberculosis (TB) project to develop a deep-sequencing assay and its tailored bio-informatics pipeline. This aims to enable early and improved diagnosis of TB when there is an increasingly drug resistant strains of TB emerging world-wide with multi-drug resistance. Under the terms of agreement, The University of Hong Kong will provide data and knowledge, while The Hong Kong Polytechnic University will insure the TB assay development required to perform NGS sequencing. This assay will be used in combination with the DeepChek(R) Tuberculosis software application. These will be validated with retrospective and prospective clinical specimens. ABL will optimize its DeepChek(R) platform technology for this TB assay with whole genome sequencing data analysis and other TB specificities. Other terms of the agreement are not disclosed.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Hong Kong Polytechnic University, please visit www.polyu.edu.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.